-+ 0.00%
-+ 0.00%
-+ 0.00%

Biotricity FY26 net loss narrows to $3.13 million; revenue rises 16% to $16 million

PUBT·07/14/2026 21:26:09
Listen to the news
Biotricity FY26 net loss narrows to $3.13 million; revenue rises 16% to $16 million
  • Biotricity reported fiscal 2026 net loss attributable to common stockholders of USD 3.13 million, narrowing from USD 11.94 million a year earlier.
  • Revenue rose 16% to USD 16 million, lifting operating results to operating income of USD 1.69 million from an operating loss of USD 2.45 million.
  • Gross margin improved 4.4 percentage points to 81%, reflecting a higher mix of technology fees, which totaled USD 14.44 million.
  • Selling, general and administrative expense fell to USD 8.49 million from USD 10.86 million, while research and development expense increased to USD 2.76 million from USD 2.16 million.
  • Cash and cash equivalents were USD 149,789 at March 31, 2026, with a working capital deficit of USD 31.3 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biotricity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-033207), on July 14, 2026, and is solely responsible for the information contained therein.